Transplant Genomics, Inc.
18
3
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
3 terminated/withdrawn out of 18 trials
40.0%
-46.5% vs industry average
11%
2 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients
Role: collaborator
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
Role: collaborator
Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation
Role: collaborator
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
Role: lead
PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients)
Role: lead
TruGraf Liver Gene Expression Serial Test
Role: collaborator
TruGraf Utilization in High IPV Levels
Role: collaborator
Diagnosis of Graft Pathology by TruGraf
Role: collaborator
RATIO: Rational Approach To Immuno-Oncology
Role: collaborator
Immune Monitoring to Facilitate Belatacept Monotherapy
Role: collaborator
TruGraf® Long-term Clinical Outcomes Study
Role: lead
CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
Role: lead
TRU-IMMUNO: Optimizing Liver Immunosuppression
Role: lead
TruGraf and TRAC In Pediatrics Study
Role: lead
Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care
Role: lead
TruGraf® Testing in High-Risk Kidney Transplant Recipients
Role: lead
Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test
Role: lead
Molecular Biomarkers in Renal Transplantation Via TruGraf® Test
Role: lead
All 18 trials loaded